240 results on '"Ferreira, Pamela C.L."'
Search Results
2. Modeling the progression of neuropsychiatric symptoms in Alzheimer’s disease with PET-based Braak staging
3. Vascular risk burden is a key player in the early progression of Alzheimer’s disease
4. Hippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies
5. Sex modulates the role of astrocyte reactivity in preclinical Alzheimer’s disease
6. Synaptic dysfunction, Tau pathology and Neurodegeneration
7. CSF total tau is more closely associated with synaptic dysfunction than overt neurodegeneration
8. Association of reactive astrogliosis and microglial activation with tau pathology in Alzheimer’s disease
9. Increased regional brain inflammation predicts longitudinal brain atrophy in individuals in the Alzheimer’s disease continuum
10. Plasma p‐tau and brain‐derived total tau biomarkers predict longitudinal changes in Aβ, tau, and cognition across the AD continuum
11. Neuroinflammation Exacerbates Irritability and Agitation in Alzheimer’s Disease
12. Association between plasma inflammatory biomarkers and [18F]FDG‐PET signal in a transgenic amyloid rat model
13. Amyloid β‐dependent tau phosphorylation is triggered by reactive astrocytes in preclinical Alzheimer’s disease
14. Association between glial and synaptic fluid biomarkers and brain [18F]FDG‐PET signal
15. APOEε4 potentiates the effects of Aβ pathology on the deposition of neurofibrillary tangles via tau phosphorylation
16. Amyloid and Tau Predominance Subtyping Identifies CI Patients With Different Clinical Phenotypes
17. Association between brain [18F]FDG‐PET signal and genetic cell markers in the brain tissue
18. Microglial activation interacts with amyloid‐β to drive longitudinal tau tangle accumulation and cognitive decline
19. Astrocyte reactivity is associated with synaptic dysfunction across the aging and Alzheimer’s disease spectrum, whereas microglial reactivity is specifically associated with synaptic dysfunction related to cognitive impairment
20. Potential utility of using both APOEε4 and Aβ positivity to enrich clinical trials of tau‐targeting therapies
21. Sex impacts the association of plasma Glial Fibrillary Acidic Protein with neurodegeneration in Alzheimer’s disease
22. Increased Genetic Risk for ADHD Potentiates Cognitive Impairment and Brain Hypometabolism in Alzheimer’s Disease Patients
23. Microglial Activation Contributes to Neuropsychiatric Dysfunction in Alzheimer’s Disease
24. Astrocyte reactivity potentiates longitudinal tau tangle accumulation in cognitively unimpaired individuals
25. A systematic evaluation of cortical GABA levels in transgenic mouse models of amyloid
26. Synapse dysfunction and astrocyte reactivity are associated independently of amyloid‐β and tau pathologies
27. A systematic evaluation of hippocampal GABA levels in transgenic mouse models of amyloid and tau
28. Plasma p‐tau181 and nfl as surrogates biomarkers in clinical trials targeting preclinical stage of Alzheimer’s disease
29. Employing transfer learning to optimize deep learning models for Alzheimer’s disease classification using two tau PET tracers
30. Associations between brain TSPO and [18F]FDG‐PET signals in neurodegenerative disorders
31. Indigenous individuals present distinct modifiable risk factors of dementia than white individuals: an ELSI‐Brazil study
32. Synaptic dysfunction in the presence of tau tangles is not a strong predictor of atrophy
33. Plasma p‐tau231 and p‐tau217 provides information on tau tangle deposition in symptomatic Alzheimer’s disease individuals
34. Blood immune response genes are correlated with brain glucose metabolism
35. Amyloid and tau‐driven signatures in hippocampal GFAP‐positive astrocytes
36. The impact of hypertension on longitudinal cognitive decline in cognitively unimpaired individuals
37. Blood protein kinase activity regulating genes are associated with brain glucose metabolism
38. Comparison of plasma amyloid, tau, and astrocyte biomarkers to identify AD pathophysiology
39. GABAergic system in Alzheimer’s disease: a systematic review with meta‐analysis
40. Amyloid and tau pathologies associate with distinct aspects of the inflammatory cascade
41. Impact of meningeal and age‐related off‐target binding on longitudinal [18F]MK6240 quantification
42. GFAP expression levels are associated with brain glucose metabolism in a rat model of Alzheimer’s disease
43. Impact of meningeal and age‐related off‐target binding on longitudinal [ 18 F]MK6240 quantification.
44. The impact of individual vascular risk factors on longitudinal neurodegeneration in cognitively unimpaired individuals
45. Genetic risk for attention‐deficit/hyperactivity disorder is associated with amyloid‐dependent cognitive decline in older adults
46. Longitudinal changes in plasma p‐tau181 as a surrogate variable to populational interventions
47. Racial disparities in predictors of dementia in a population‐based cohort
48. Apolipoprotein E ε4 associates with microglial activation in early Braak regions independently of amyloid‐β and tau
49. Temporal evaluation of imaging and biofluid biomarkers, spatial neuropathology and glial function in the TgF344‐AD rat model.
50. Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.